Datos del Documento


Por favor, use este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/8585
Registro de Metadatos Completo
Campo Dublin Core Valor Idioma
dc.contributor.authorEspina, Marta-
dc.contributor.authorCorte Rodríguez, Mario-
dc.contributor.authorAguado, Leticia-
dc.contributor.authorMontes Bayón, María-
dc.contributor.authorSierra, Marta-
dc.contributor.authorMartínez Camblor, Pablo-
dc.contributor.authorBlanco González, Elisa-
dc.contributor.authorSierra Zapico, Luisa María-
dc.date.accessioned2017-09-28T07:09:50Z-
dc.date.available2017-09-28T07:09:50Z-
dc.date.issued2017-04-07-
dc.identifier.citationMarta Espina, Mario Corte-Rodríguez, Leticia Aguado, María Montes-Bayón, Marta I. Sierra, Pablo Martínez-Camblor, Elisa Blanco-González, L. María Sierra. Metallomics. 2017; 9: 564-574eng
dc.identifier.otherDOI: 10.1039/c7mt00014f-
dc.identifier.urihttps://ria.asturias.es/RIA/handle/123456789/8585-
dc.description.abstractCisplatin, one of the most extensively used metallodrugs in cancer treatment, presents the important drawback of patient resistance. This resistance is the consequence of different processes including those preventing the formation of DNA adducts and/or their quick removal. Thus, a tool for the accurate detection and quantitation of cisplatin-induced adducts might be valuable for predicting patient resistance. To prove the validity of such an assumption, highly sensitive plasma mass spectrometry (ICP-MS) strategies were applied to determine DNA adduct levels and intracellular Pt concentrations. These two metal-relative parameters were combined with an evaluation of biological responses in terms of genomic stability (with the Comet assay) and cell cycle progression (by flow cytometry) in four human cell lines of different origins and cisplatin sensitivities (A549, GM04312, A2780 and A2780cis), treated with low cisplatin doses (5, 10 and 20 mM for 3 hours). Cell viability and apoptosis were determined as resistance indicators. Univariate linear regression analyses indicated that quantitation of cisplatin-induced G–G intra-strand adducts, measured 1 h after treatment, was the best predictor for viability and apoptosis in all of the cell lines. Multivariate linear regression analyses revealed that the prediction improved when the intracellular Pt content or the Comet data were included in the analysis, for all sensitive cell lines and for the A2780 and A2780cis cell lines, respectively. Thus, a reliable cisplatin resistance predictive model, which combines the quantitation of adducts by HPLC-ICP-MS, and their repair, with the intracellular Pt content and induced genomic instability, might be essential to identify early therapy failure.eng
dc.description.sponsorshipEste trabajo fue patrocinado por el Ministerio de Educación y Ciencia español (MEC, número de protecto CTQ2010-16638); el Ministerio de Economía y Comercio (MINECO, número de proyecto: CTQ2013-39032-C2-1-R); y el Programa Regional de Investigación del Principado de Asturias (número de proyecto: FC-15-GRUPIN14-010). Marta Espina fue patrocinada por una beca FPU (MEC, España) y Mario Corte Rodríguez por la beca predoctoral Severo Ochoa (BP13114, Plan Regional de Investigación del Principado de Asturias, FICYT)eng
dc.language.isoengeng
dc.publisherThe Royal Society of Chemistryeng
dc.relation.ispartofMetallomicseng
dc.relation.haspart9eng
dc.relation.isreferencedbyNo, esta versión no ha sido citadaeng
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.source564;574-
dc.subject.classificationPublicadoeng
dc.titleCisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failureeng
dc.typearticleeng
Aparece en las colecciones: Open Access DRIVERset
Química

Archivos en este documento:
Fichero Tamaño Formato  
Archivo.pdf1.86 MBAdobe PDFVer/Abrir
Mostrar el registro Básico


Ver estadísticas del documento


Este documento está sujeto a una licencia Creative Commons: Licencia Creative Commons Creative Commons